alamar

Alamar Biosciences Announces Launch of NULISAqpcr AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the…

2 weeks ago

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investorsStephen Williams, MD, Ph.D. joins as Chief Scientific OfficerRebecca…

2 weeks ago

Alamar Biosciences Launches NULISAqpcr BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer’s Disease Research

New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next generation of assay development.  FREMONT, Calif., Oct. 9,…

4 months ago

Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort

NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 to Power Biomarker Discovery in 23,000 Longitudinal Samples FREMONT, Calif., July…

6 months ago

Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer’s Association International Conference (AAIC)

Groundbreaking Insights into Neurodegenerative Disease Biomarkers to be Unveiled through 30+ Posters and Presentations at International Meeting FREMONT, Calif., July…

6 months ago

Alamar Biosciences, Alzheimer’s Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer’s Disease.

Multi-center project will profile over 40,000 samples using ultra-sensitive NULISA™ technology. FREMONT, Calif., June 10, 2025 /PRNewswire/ -- Alamar Biosciences,…

8 months ago